What metrics can be used to ensure value-based alignment when treating Hepatitis C in opioid treatment centers?
Subset of Metrics for Prevention and Treatment of Infectious Disorders Including Hepatitis C and HIV MVP (M1368)
First Published: March 11, 2026
Disclaimer: This is not legal nor medical advice. Consult with your own attorney and with a licensed medical providers on the proper implementation of a Hepatitis C care program.
This is an early draft intended to be used as demonstrative documentation for providers working with Empath Medical Innovations under a Business Associate Agreement to treat Hepatitis C in opioid use disorder clinics. While it may be of interest to other parties and the public at-large, it is not intended for general use or as a resource for any other setting. By staying on this page, you agree to waive any and all claims against Empath Medical Innovations for any damages or liabilities you may incur from relying on the information published here. Please close your browser window and cease using our website if you do not agree to waive any and all such claims against Empath.
Hepatitis C is grouped with HIV and infectious disease in general under the MIPS value pathway M1368. Of critical importance, the sustained viral response for HCV was added as a high-priority outcome in 2026, with changes retroactive for patients treated in 2025. It's designation as an outcome measure makes it's reporting mandatory for all participating providers.
Quality
Providers can select 4 of of the quality measures contained in M1368. We document and assess all HCV-specific measures (3 measures), and we also include HIV screening as standard practice to develop the HCV treatment plan for HCV positive patients. We also collect and store information on the remaining metrics if the patient presents comorbidity with HIV or other applicable infectious diseases.
Mandatory HCV Metrics
Q516: Hepatitis C Virus (HCV): Sustained Virological Response (SVR) (Mandatory for all participating providers)
Q387: Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users - 2025_Measure_387_MIPSCQM.pdf
Q401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis - 2025_Measure_401_MIPSCQM.pdf
Q475: HIV Screening (only for HCV-positive patients) - Online eCQM
Staff and clinicians at affiliated providers can view real-time (pre-audit) reports on all metrics for their location by visiting their Dashboard.